Enhanced Liver Fibrosis Score Stratifies Hepatocellular Carcinoma Risk in Patients With Hepatitis B Surface Antigen Seroclearance

被引：5
|
作者：
Mak, Lung-Yi [1 ,2 ]
Cheung, Ka-Shing [1 ,3 ]
Hui, Rex Wan-Hin [1 ]
Wong, Danny Ka-Ho [1 ,2 ]
Fung, James [1 ,2 ]
Yuen, Man-Fung [1 ,2 ]
Seto, Wai-Kay [1 ,2 ,3 ]
机构：
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Pokfulam Rd 102, Hong Kong, Peoples R China
[2] Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China
[3] Univ Hong Kong, Dept Med, Shenzhen Hosp, Shenzhen, Peoples R China
来源：
CLINICAL INFECTIOUS DISEASES | 2022年 / 75卷 / 12期
关键词：
hepatitis B virus (HBV); enhanced liver fibrosis (ELF); functional cure; hepatocellular carcinoma ( HCC); HBSAG SEROCLEARANCE;
D O I：
10.1093/cid/ciac387
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
In this prospective study involving 337 chronic hepatitis B patients who achieved spontaneous hepatitis B surface antigen (HBsAg) seroclearance (SC), serum enhanced liver fibrosis (ELF) before SC was associated with hepatocellular carcinoma (HCC) (hazard ratio 2.588), and ELF 97% reduction in risk of HCC development in patients with age SC >= 50 (n = 190).
引用
收藏
页码：2257 / 2259
页数：3
相关论文
共 50 条
  • [21] Risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance - a territory-wide analysis of 5181 patients
    Chan, H. L. Y.
    Yip, T. C. F.
    Wong, V. W. S.
    Tse, Y. K.
    Wong, G. L. H.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S15 - S16
  • [22] Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen
    Yip, Terry Cheuk-Fung
    Wong, Vincent Wai-Sun
    Chan, Henry Lik-Yuen
    Tse, Yee-Kit
    Kong, Alice Pik-Shan
    Lam, Kelvin Long-Yan
    Lui, Grace Chung-Yan
    Wong, Grace Lai-Hung
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2018, 16 (05) : 765 - +
  • [23] Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis
    Song, Aixin
    Wang, Xiaoxiao
    Lu, Junfeng
    Jin, Yi
    Ma, Lina
    Hu, Zhongjie
    Zheng, Yanhong
    Shen, Chengli
    Chen, Xinyue
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (04) : 601 - 612
  • [24] Reply to: "A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Considerations"
    Yang, Hyun
    Bae, Si Hyun
    Jang, Jeong Won
    JOURNAL OF HEPATOLOGY, 2022, 77 (06) : 1724 - 1725
  • [25] Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma
    Chen, Y. C.
    Liaw, Y. F.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (02) : 210 - 211
  • [26] Metabolic-Associated Fatty Liver Disease, Hepatitis B Surface Antigen Seroclearance, and Long-Term Risk of Hepatocellular Carcinoma in Chronic Hepatitis B
    Yu, Ming-Whei
    Lin, Chih-Lin
    Liu, Chun-Jen
    Wu, Wan-Jung
    Hu, Jui-Ting
    Huang, Yi-Wen
    CANCERS, 2022, 14 (23)
  • [27] Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance
    Gounder, P. P.
    Bulkow, L. R.
    Snowball, M.
    Negus, S.
    Spradling, P. R.
    Simons, B. C.
    McMahon, B. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (11) : 1197 - 1207
  • [28] A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!
    Lu, Wentian
    JOURNAL OF HEPATOLOGY, 2024, 80 (06) : e267 - e268
  • [29] CAMP-B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance
    Lee, Hye Won
    Yip, Terry Cheuk-Fung
    Wong, Vincent Wai-Sun
    Lim, Young-Suk
    Chan, Henry Lik-Yuen
    Ahn, Sang Hoon
    Wong, Grace Lai-Hung
    Choi, Jonggi
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (10) : 1223 - 1235
  • [30] Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance
    Fung, James
    Cheung, Ka-Shing
    Wong, Danny Ka-Ho
    Mak, Lung-Yi
    To, Wai-Pan
    Seto, Wai-Kay
    Lai, Ching-Lung
    Yuen, Man-Fung
    HEPATOLOGY, 2018, 68 (02) : 462 - 472
12345